Thiazolidinediones (TZD) have been shown to have anti-diabetic effects including the ability to decrease fasting hyperglycemia and hyperinsulinemia, increase insulin-mediated glucose disposal rate (M) and decrease hepatic glucose production, but the mechanisms of action are not well established. To determine whether a TZD (R-102380, Sankyo Company Ltd., Tokyo, Japan) could improve insulin action on skeletal muscle glycogen synthase (GS), the rate-limiting enzyme in glycogen synthesis, 4 insulin-resistant obese monkeys were given I mg/kg/ day R-102380 p.o. for a 6-week period. Skeletal muscle GS activity and glucose 6-phosphate (G6P) content were compared between pre-dosing and dosing periods before and during the maximal insulin-stimulation of a euglycemic hyperinsulinemic clamp.
INTRODUCTION
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RESULTS
The characteristics of the individual rhesus monkeys before and at the end of the six-week TZD treatment period are shown in Table I Figure 2 , with independent, total, and fractional activity shown for the pre-dosing period and during dosing. For the group as a whole, the basal glycogen synthase activities were not significantly effected by R-102380 (pre-R-102380 The greatest absolute increase in glycogen synthase independent activity and in glycogen synthase fractional activity with R-102380 treatment was observed in the most diabetic monkey (J-8), the monkey that also showed the greatest increase in whole-body insulin sensitivity as measured by the euglycemic hyperinsulinemic clamp.
Basal glucose 6-phosphate content was not significantly effected by R-102380 (0.47 4-0.17 vs. 0.734-0.15 nmol/mg dry weight, p=0.13). Glucose 6-phosphate content under insulinstimulated conditions was significantly higher during dosing (0.43 4-0.08 nmol/mg dry weight) than before dosing (0.27 4-0.09nmol/ mg dry weight) (p 0.02) (Fig. 3) . (Fig. 3) . Basal vs. insulin-stimulated glucose 6-phosphate Ka of glycogen synthase during dosing approached significance (p 0.07). The effect of insulin to covalently activate muscle glycogen synthase was strongly related to wholebody insulin-mediated glucose disposal rate in these monkeys.
I161
In the present study of insulin-resistant rhesus monkeys, 6 [14] [15] [16] neither has it been shown to increase protein expression or mRNA expression in humans. [12" 22, 23] In summary, the thiazolidinedione R-102380 improves in vivo insulin action on skeletal muscle glycogen synthase in insulin-resistant rhesus monkeys; this may be an important mechanism by which thiazolidinediones improve insulin sensitivity. The effect of R-102380 to increase glycogen synthase total activity during a euglycemic hyperinsulinemic clamp warrants the future investigation of the effect of thiazolidinediones on skeletal muscle glycogen synthase protein and mRNA expression.
